The Sanford Project & DiaMedica to Present Preclinical Abstract on DM-199 Treatment of Type 1 Diabetes at the 73rd Annual ADA Conference
June 20, 2013 08:47 ET
|
DiaMedica Inc.
SIOUX FALLS, SOUTH DAKOTA and MINNEAPOLIS, MINNESOTA--(Marketwired - June 20, 2013) - The Sanford Project & DiaMedica (TSX VENTURE:DMA), announced today that their abstract titled...
DiaMedica Announces Initiation of Phase I/II Clinical Trial for Potential First-in-Class Treatment of Type 2 Diabetes
May 01, 2013 08:07 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - May 1, 2013) - DiaMedica Inc. (TSX VENTURE:DMA) announces the commencement of its Phase I/II trial with first in human dosing of DM-199; a...
DiaMedica Receives Phase I/II Clinical Trial Regulatory Approval for DM-199 as a Potential Treatment for Diabetes
April 08, 2013 08:44 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - April 8, 2013) - DiaMedica (TSX VENTURE:DMA), is pleased to announce it has received regulatory approval to commence an anticipated 76 subject Phase...
DiaMedica Inc. Announces Completion of $4.6 Million Prospectus Offering
March 22, 2013 09:02 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwire - March 22, 2013) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
DiaMedica Inc....
DiaMedica Inc. Announces Filing of Final Prospectus
March 15, 2013 12:54 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwire - March 15, 2013) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
DiaMedica Inc. (TSX VENTURE:DMA),...
DiaMedica Inc. Announces Public Offering
February 25, 2013 22:05 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwire - Feb. 25, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), announced today that it has filed a preliminary short form prospectus in connection with the...
DiaMedica Announces Resignation of Board Member
February 22, 2013 18:35 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwire - Feb. 22, 2013) - DiaMedica (TSX VENTURE:DMA) announces today that David Allan has resigned from the Company's board of directors, effective February...
DiaMedica to Present at 15th Annual BIO CEO & Investor Conference
February 05, 2013 08:30 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwire - Feb. 5, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), a biotechnology company focused on developing novel treatments for diabetes, announced that Mr....
DiaMedica Successfully Completes DM-199 cGMP Manufacturing and Pre-clinical Toxicology Safety Studies
January 29, 2013 08:00 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwire - Jan. 29, 2013) - DiaMedica (TSX VENTURE:DMA) has successfully completed cGMP manufacturing of DM-199 to be utilized in upcoming clinical trials....
DiaMedica Announces the Appointment of Dr. Mark Robbins as Vice President, Clinical and Regulatory Affairs
January 09, 2013 07:00 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwire - Jan. 9, 2013) - DiaMedica (TSX VENTURE:DMA) is pleased to announce that Mark Robbins, Ph.D., J.D., has joined as Vice President, Clinical and...